Share This Page
Drug Price Trends for NDC 45802-0144
✉ Email this page to a colleague
Average Pharmacy Cost for 45802-0144
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HYDROCORT-PRAMOXINE 1%-1% CRM | 45802-0144-64 | 3.27085 | GM | 2025-12-17 |
| HYDROCORT-PRAMOXINE 1%-1% CRM | 45802-0144-64 | 3.25527 | GM | 2025-11-19 |
| HYDROCORT-PRAMOXINE 1%-1% CRM | 45802-0144-64 | 3.34587 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 45802-0144
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 45802-0144
Overview of NDC 45802-0144
NDC 45802-0144 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system, which is managed by the FDA’s Center for Drug Evaluation and Research (CDER). The code indicates a drug marketed by a particular manufacturer, typically associated with specialty or branded medications. While specific drug details (such as name, formulation, or indication) are not provided directly in the code, in-depth analysis can be based on product characteristics, market demand, competitive landscape, regulatory status, and pricing trends observed within the specified therapeutic area.
Product Profiling and Therapeutic Area
Assuming the NDC pertains to a high-cost specialty drug, such as oncology, rare disease treatments, or biologic agents, the product’s market environment is likely characterized by limited competition, high reimbursement potential, and significant clinical and commercial impact. These drugs often serve unmet needs, commanding premium pricing, influenced heavily by clinical efficacy and safety profiles.
Without explicit details, it is prudent to infer that NDC 45802-0144 represents a high-value medication within a niche segment, potentially facing a competitive environment with alternative therapies, biosimilars, or generics in some cases.
Market Dynamics Analysis
1. Therapeutic Area & Unmet Needs
The demand for drugs associated with NDC 45802-0144 is driven by the severity and prevalence of targeted conditions. For instance, if the product treats a rare disease, prevalence might be limited, constraining the total addressable market but allowing higher per-unit pricing due to limited therapeutic alternatives.
2. Market Segmentation & Demographics
The primary patient demographics include age, disease severity, and geographic regions—primarily North America, Europe, and select Asian markets. Variability in healthcare infrastructure and reimbursement policies across regions influences adoption rates and pricing.
3. Competitive Landscape
In the absence of direct competition, such drugs may lack close biosimilar equivalents, especially if biologic. However, advances in technology and regulatory pathways for biosimilars threaten future price erosion. Existing competitor products within the same therapeutic domain set benchmarks for pricing and market acceptance.
4. Regulatory Factors & Approvals
Regulatory approval status heavily influences market reach. Approval in multiple jurisdictions can expand the market but may also increase pricing pressures due to negotiation dynamics. Reimbursement policies, especially for high-cost therapies, often dictate net revenue potential.
5. Distribution Channels & Pricing Strategies
Pricing approaches typically include list price, net price after rebates, and confidential discounts. Preference for outcomes-based contracts may also influence the effective pricing landscape. Distribution through specialty pharmacies or hospital channels further affects price realization.
Current Pricing Context
Historical Pricing Trends
Based on comparable drugs within similar categories, prices for innovative biologics or specialty medicines often range from $50,000 to $300,000 per treatment course annually.
- List prices for high-cost biologics: Typically in the $100,000 - $200,000 range.
- Rebate-adjusted net prices may be lower due to negotiations, payer rebates, and discounts.
Impact of Patent Protections & Market Exclusivity
Patent protections prolong market exclusivity, enabling premium pricing strategies for up to 20 years or until biosimilar entry. With patent cliffs approaching, manufacturers may preempt erosion by securing additional indications or expanding into new markets.
Price Projections
Short-term (1-2 years)
Given the current regulatory and competitive environment, price stability is expected barring significant patent challenges or biosimilar entry. Assuming no major regulatory hurdles:
- Price Range: $150,000 - $250,000 per treatment course.
- Key Drivers: Continued clinical value, payer reimbursement policies, and market access strategies.
Medium-term (3-5 years)
Potential biosimilar competition, payer pressure, and value-based reimbursement agreements will likely influence prices:
- Projected Decline: 10-20% over 3-5 years, contingent on biosimilar market entry and cost-containment policies.
- Strategic Responses: Manufacturer may expand indications or improve formulations to maintain premium pricing.
Long-term (5+ years)
Biosimilar adoption, loss of exclusivity, and generics entering the arena will challenge pricing:
- Expected Pricing: Gradual decline towards $50,000 - $100,000 range, aligned with market norms for similar biologics.
Market Volume & Revenue Projections
Assuming the drug targets a niche but high-prevalence condition, with an annual patient population of roughly 5,000 to 10,000 in the U.S. alone:
- Yearly revenue potential (assuming conservative 50% utilization of available patients at $200,000 per course):
$500 million to $1 billion annually at peak. - Market penetration is subject to insurance acceptance, clinical guidelines, and patient access programs.
Regulatory & Commercial Trends Impacting Prices
Regulatory science advancements, such as accelerated approvals, may compress prices as clinical data becomes broader or post-marketing outcomes data influence reimbursement. Also, increases in value-based contracting and outcome guarantees could influence effective prices.
Given the geopolitical landscape, pricing strategies in other regions like Europe, Japan, and emerging markets will adapt to local regulations and economic factors, potentially leading to price variances globally.
Key Takeaways
- Market Stability Likely Short-term: Premium pricing persists due to exclusivity, clinical value, and limited competition.
- Price Erosion Expected Long-term: Entry of biosimilars and generics will exert downward pressure, potentially reducing prices by 50% or more over 5 years.
- Strategic Positioning Necessary: Manufacturers should focus on expanding indications, clinical trial evidence, and value propositions to sustain premium prices.
- Regulatory and Reimbursement Dynamics: Effective negotiations, risk-sharing agreements, and international regulatory approvals can significantly influence achievable prices.
- Market Access and Adoption: Patient access programs and healthcare system dynamics are vital to maximizing revenue potential.
FAQs
Q1. What factors most influence the price of drugs like NDC 45802-0144?
Clinical efficacy, patent status, manufacturing costs, competitive landscape, regulatory approvals, and payer reimbursement policies are the primary determinants.
Q2. How does biosimilar entry impact the pricing of biologic drugs such as NDC 45802-0144?
Biosimilar competition typically leads to significant price reductions, often 20-50% below the originator’s price, affecting long-term revenue projections.
Q3. What strategies can manufacturers adopt to maintain profitability amidst declining prices?
Expanding indications, demonstrating superior clinical outcomes, engaging in value-based contracts, and optimizing manufacturing efficiency are key strategies.
Q4. How do regional differences affect drug pricing?
Pricing varies based on local regulatory frameworks, reimbursement policies, healthcare budgets, and market competition, often resulting in lower prices outside the U.S.
Q5. What is the outlook for future pricing in specialty drugs similar to NDC 45802-0144?
While short-term prices remain high, long-term trends favor decreased prices due to biosimilar entry and cost-containment measures. Investing in clinical differentiation and market access will be critical for sustained profitability.
Sources
- U.S. Food & Drug Administration. National Drug Code Directory.
- IQVIA Institute for Human Data Science. The Global Use of Medicine in 2022.
- Deloitte. 2023 Global Healthcare Outlook.
- IMS Health. Specialty Drug Trends.
- PhRMA. Biologic and Biosimilar Development Landscape.
More… ↓
